Elan (ELN) Restructures Tysabri Collaboration w/ Biogen (BIIB); Will Get $3.25B Upfront
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital Downgrades Elan Corp (ELN) to Sector Perform
February 7, 2013 9:15 AM ESTRBC Capital downgraded Elan Corp (NYSE: ELN) from Outperform to Sector Perform with a price target of $11.00 (from $15.00) following sale of Tysabri rights.
For an analyst ratings summary and ratings history on Elan Corp... More
Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal
February 6, 2013 3:50 PM ESTDeutsche Bank raised its price target on Buy-rated Biogen (NASDAQ: BIIB) from $160 to $170 following the news the company acquired 100% rights for Tysabri from ELAN (NYSE: ELN) for an upfront payment of $3.25B and contingent royalty payments based... More
Deutsche Bank Downgrades Elan Corp (ELN) to Hold; Post Tysabri Deal M&A Activity in Focus
February 6, 2013 3:46 PM ESTDeutsche Bank downgraded Elan Corp (NYSE: ELN) from Buy to Hold with a EUR 7.60 price target following the sale of Tysabri to Biogen.
The firm comments, "Elans decision to cede control of Tysabri to Biogen seems to be an attractive... More
